PL1830924T3 - Zapobieganie tworzeniu i/lub stabilizacji skrzepu - Google Patents

Zapobieganie tworzeniu i/lub stabilizacji skrzepu

Info

Publication number
PL1830924T3
PL1830924T3 PL05820601T PL05820601T PL1830924T3 PL 1830924 T3 PL1830924 T3 PL 1830924T3 PL 05820601 T PL05820601 T PL 05820601T PL 05820601 T PL05820601 T PL 05820601T PL 1830924 T3 PL1830924 T3 PL 1830924T3
Authority
PL
Poland
Prior art keywords
stabilization
prevention
thrombus formation
thrombus
formation
Prior art date
Application number
PL05820601T
Other languages
English (en)
Inventor
Bernhard Nieswandt
Thomas Renne
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL1830924T3 publication Critical patent/PL1830924T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05820601T 2004-12-23 2005-12-20 Zapobieganie tworzeniu i/lub stabilizacji skrzepu PL1830924T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04030593 2004-12-23
PCT/EP2005/013714 WO2006066878A1 (en) 2004-12-23 2005-12-20 Prevention of thrombus formation and/or stabilization
EP05820601A EP1830924B1 (en) 2004-12-23 2005-12-20 Prevention of thrombus formation and/or stabilization

Publications (1)

Publication Number Publication Date
PL1830924T3 true PL1830924T3 (pl) 2013-08-30

Family

ID=34927953

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05820601T PL1830924T3 (pl) 2004-12-23 2005-12-20 Zapobieganie tworzeniu i/lub stabilizacji skrzepu

Country Status (14)

Country Link
US (3) US8119137B2 (pl)
EP (2) EP2272565A3 (pl)
JP (1) JP5118492B2 (pl)
KR (1) KR101277097B1 (pl)
CN (1) CN101102819A (pl)
AU (1) AU2005318464B2 (pl)
BR (1) BRPI0519349A8 (pl)
CA (1) CA2591786C (pl)
DK (1) DK1830924T3 (pl)
ES (1) ES2407965T3 (pl)
MX (1) MX2007006997A (pl)
PL (1) PL1830924T3 (pl)
RU (1) RU2514878C2 (pl)
WO (1) WO2006066878A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2386310T3 (en) 2002-08-28 2019-02-25 Dyax Corp Methods of preserving organs and tissues
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2109457B1 (en) * 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
CA2695012A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
AU2008315938B2 (en) * 2007-10-22 2014-11-27 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
EP2103311A1 (en) 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
EP2145900A1 (en) 2008-07-15 2010-01-20 CSL Behring GmbH Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP2269597A1 (en) 2009-06-22 2011-01-05 CSL Behring GmbH CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis
EP2272874A1 (en) 2009-07-10 2011-01-12 CSL Behring GmbH Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
US9150864B2 (en) * 2010-11-08 2015-10-06 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
WO2012120128A1 (en) 2011-03-09 2012-09-13 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
CN103687878B (zh) * 2011-07-22 2018-01-09 德国杰特贝林生物制品有限公司 抑制性的抗因子xii/xiia单克隆抗体及其用途
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
US20140296146A1 (en) * 2011-08-23 2014-10-02 Synapse B.V. Thermostable Inhibitors of Activation of the Blood Clotting System Through Contact with Foreign Surfaces
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US9574013B2 (en) * 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
AU2014224599B2 (en) 2013-03-08 2018-11-08 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
JP2017501968A (ja) * 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
US20170114119A1 (en) * 2014-06-18 2017-04-27 Csl Behring Gmbh Therapy using a factor xii inhibitor in a neurotraumatic disorder
AU2015373910B2 (en) 2015-01-02 2021-11-18 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
CA2982413A1 (en) * 2015-04-28 2016-11-03 Ecole Polytechnique Federale De Lausanne (Epfl) Novel inhibitors of the enzyme activated factor xii (fxiia)
IL257047B1 (en) 2015-07-21 2024-07-01 Dyax Corp A monoclonal antibody that inhibits factor XIIA
JP7003354B2 (ja) 2015-12-11 2022-03-04 武田薬品工業株式会社 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
EP3440107A4 (en) 2016-04-06 2020-02-19 CSL Limited METHOD FOR TREATING ATHEROSCLEROSIS
US11505619B2 (en) 2017-12-15 2022-11-22 Csl Limited Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
CA3104470A1 (en) * 2018-06-19 2019-12-26 Regeneron Pharmaceuticals, Inc. Anti-factor xii/xiia antibodies and uses thereof
EP3886982A1 (en) * 2018-11-28 2021-10-06 Oregon Health & Science University Therapeutic factor xii antibody
CA3145299A1 (en) 2019-07-08 2021-01-14 Rezolute, Inc. Processes for preparing plasma kallikrein inhibitors
JP7088892B2 (ja) 2019-10-11 2022-06-21 イビデン株式会社 組電池用断熱シート及び組電池
WO2021253662A1 (zh) * 2020-06-16 2021-12-23 宁波康善生物科技有限公司 抗fxii纳米抗体或其抗原结合片段及其应用
TW202242111A (zh) 2020-12-18 2022-11-01 美商Ionis製藥公司 用於調節因子ｘｉｉ之化合物及方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK225488D0 (da) * 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US4963657A (en) * 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1994020535A1 (en) * 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
JP3929484B2 (ja) 1993-09-14 2007-06-13 ジェネンテック・インコーポレーテッド エコチンおよびその同族体を含む医薬的組成物
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DE19725014A1 (de) * 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
GB9800817D0 (en) 1998-01-16 1998-03-11 Bio Discovery Ltd Serine protease inhibitors
DE69919702T2 (de) * 1998-06-08 2005-09-15 The University Of Vermont And State Agricultural College Verfahren zur Bestimmung der Blutgerinnung in Plasma
AU760735B2 (en) * 1998-09-28 2003-05-22 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
EP1222929B8 (en) * 2001-01-11 2010-07-07 Life Sciences Research Partners VZW Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
CA2488558C (en) * 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US20060093595A1 (en) 2002-07-05 2006-05-04 Mahesh Jayachandra Methods, compositions and kits for treating damage to excitable tissue
DK2386310T3 (en) * 2002-08-28 2019-02-25 Dyax Corp Methods of preserving organs and tissues
US20040229778A1 (en) * 2003-05-13 2004-11-18 Elmaleh David R. Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
PL1626736T3 (pl) 2003-05-16 2021-05-04 Pharming Intellectual Property B.V. Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego
US8152750B2 (en) * 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
GB0411145D0 (en) 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
GB0418877D0 (en) 2004-08-24 2004-09-29 Univ Edinburgh Heart
US20060104944A1 (en) * 2004-11-18 2006-05-18 Mousa Shaker A Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use
ES2346755T3 (es) 2004-12-01 2010-10-20 Par Pharmaceuticals, Inc. Uso de acetato de megestrol para mejorar la funcion cardiaca y el tratamiento de la insuficiencia cardiaca.

Also Published As

Publication number Publication date
DK1830924T3 (da) 2013-05-21
US8715672B2 (en) 2014-05-06
WO2006066878A1 (en) 2006-06-29
AU2005318464A1 (en) 2006-06-29
US20080254039A1 (en) 2008-10-16
US8119137B2 (en) 2012-02-21
CA2591786A1 (en) 2006-06-29
AU2005318464B2 (en) 2012-02-23
EP2272565A2 (en) 2011-01-12
MX2007006997A (es) 2007-10-10
JP5118492B2 (ja) 2013-01-16
EP1830924A1 (en) 2007-09-12
BRPI0519349A8 (pt) 2017-09-12
BRPI0519349A2 (pt) 2009-01-20
RU2007123797A (ru) 2009-01-10
EP2272565A3 (en) 2012-03-28
EP1830924B1 (en) 2013-02-27
CN101102819A (zh) 2008-01-09
KR101277097B1 (ko) 2013-06-20
CA2591786C (en) 2013-07-16
US20120148688A1 (en) 2012-06-14
JP2008525342A (ja) 2008-07-17
RU2514878C2 (ru) 2014-05-10
US20130164301A1 (en) 2013-06-27
ES2407965T3 (es) 2013-06-17
KR20070092303A (ko) 2007-09-12

Similar Documents

Publication Publication Date Title
PL1830924T3 (pl) Zapobieganie tworzeniu i/lub stabilizacji skrzepu
AP2007004245A0 (en) Compounds and methods for the treatment or prevention of flavivirus infections
IL188832A0 (en) Systems and methods for stabilization of bone structures
EP1744744A4 (en) BIOACTIVE COMPOUNDS AND METHODS OF USE THEREOF
EP1617805A4 (en) METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
IL209849A0 (en) Sclerostin and the inhibition of wnt signaling and bone formation
IL182203A0 (en) Thiadiazole compounds and methods of use
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
HK1118186A1 (en) Osteosynthetic implants and methods of use and manufacture
IL182734A0 (en) 4-aminotetracyclines and methods of use thereof
HK1107503A1 (en) Cheese and methods of making such cheese
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
EP1865972A4 (en) TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS
EP2135078A4 (en) METHODS OF IDENTIFYING AGENTS AND THEIR USE IN PREVENTING OR STABILIZING FIBROSIS
IL174577A0 (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
GB0404656D0 (en) Treatment of spinal conditions
EP1833509A4 (en) DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
EP1817039A4 (en) TREATMENT AND PREVENTION OF EPILEPSY
PL1773122T3 (pl) Zastosowanie orto-fenylofenolu i/lub jego pochodnych do zahamowania bezpłciowego rozmnażania grzybów
GB0504657D0 (en) Compositions and methods of treatment
IL166083A0 (en) Methods for treatment and prevention of gastrointestinal conditions
IL165870A0 (en) Use of chymase inhibitors for the prevention and/or